Rothnie KJ, Bancroft T, Bogart M, et al. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. Is the top shelf of a pharmacy-grade storage unit acceptable for vaccine storage if there is a fan directly above it? 1. POSTER: Management of Immune-Related Adverse Events in Patients with Solid Tumors Treated with Dostarlimab in the GARNET Study, 3. Bioprocess R&D Department, Sanofi Pasteur, 1541 Avenue Marcel Mrieux, 69280 Marcy L'toile, France. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. POSTER: Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS), 2. Anderson M, Drummond MB, Jain R, et al. POSTER: The Burden of Illness and the Incremental Burden of Transfusion Dependence in Myelofibrosis in the United States, 11. Stability Calculator, Click here if you are not a US Healthcare Professional, Patient, or Caregiver. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS 2022), 2. 2. Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer, 1. ORAL PRESENTATION: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 2. 373. Real-World Average Dose of PARP Inhibitors Used as Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer, 1. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. Immunol Rev. Angevin E, Barnette MS, Bauer TM, et al. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. POSTER: Unmet needs in metastatic synovial sarcoma across EU-5 countries, 6. You are using an unsupported browser.Some features of this site may not function properly. 2015;21(8):914-921. PMID . 2018;22(6):527-545. Causes of Death in Patients with Anemia of Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial, 10. POSTER: Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in Real-Life Setting: The ALFA Study, 6. ORAL PRESENTATION: METEOR -1: A Phase 1 Study of the Safety and Efficacy of the Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor GSK3326595 in Advanced Solid Tumors, 2. 1. Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab. POSTER: ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC), 3. Characteristics and Inpatient Outcomes of Hospitalized Patients with COVID-19 A Population Study. Views of US pulmonologists on the prevalence of uncontrolled asthma, treatment decisions and the role of treatable traits: results from the CHEST Pulse Surveys. [Poster No. temperature excursion. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. 4. Poster No. Encore: Open-label Pilot Study of Genetically Engineered NY-ESO-1Specific T Cells (GSK3377794) Alone or in Combination With Pembrolizumab in Relapsed/Refractory Multiple Myeloma [Publication only], Pilot Neoadjuvant Study of Niraparib in HER2-Negative, BRCA-Mutated Resectable Breast Cancer, 1. CD96 is an immune checkpoint protein expressed on T cells and natural killer (NK) cells in multiple tumor types. Singh, AK et al. Averell CM, Hahn BA, Zografos L, et al. 1. POSTER: Time to next treatment (TTNT) of first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC) patients (pts) in the CHAR1ZMA study, 2. 12. [Poster No. A Phase 1 Study of TSR-022 (Anti-TIM-3) in Combination with Dostarlimab (TSR-042, Anti-PD-1), 2. A Phase 1 Dose Escalation Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors, 3. * * Fahrenheit Celsius Real-World Effectiveness of Belimumab in Patients With SLE in the US, 1. Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs. Plain Language Summary [HCP USE ONLY]: The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-Analysis, 15. P1481. GSK3174998 is a humanized immunoglobulin 1 (IgG1) OX40 agonist antibody that can enhance the proliferation and survival of CD4+ and CD8+ T cells and deplete tumor-infiltrating regulatory T cells via antibody-dependent cell cytotoxicity or phagocytosis. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. 11. Psychometric Properties of the SF-36 Vitality Scale in Patients With Anemia of Chronic Kidney Disease, 2. PRMT5 is overexpressed in multiple tumor types, including lymphoma and breast, lung, and bladder cancer, and regulates splicing, gene expression, and activation of p53. 2015;5:34, Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. P1444. POSTER: RSVPreF3 OA Candidate Vaccine Efficacy Presentation. This page has an error. Immunotherapy. GARNET: Preliminary Safety, Efficacy, Pharmacokinetic, and Biomarker Characterization from a Phase 1 Clinical Trial of TSR-042 (Anti-PD-1 Monoclonal Antibody) in Patients with Recurrent/Advanced NSCLC, 4. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. POSTER: A subgroup analysis of response rate by patient characteristics in patients with endometrial cancer receiving monotherapy dostarlimab in the GARNET trial, 8. Bogart M, Bengtson L, Rothnie K, et al. Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count, 9. 2. 1. Schwarz TF et al. 1. PUBLICATION ONLY: STING Agonist GSK3745417 Induces Apoptosis, Antiproliferation, and Cell Death in a Panel of Human AML Cell Lines and Patient Samples, 1.POSTER: Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network (Presentation Posted With Permission), 2. POSTER: Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study, 7. DREAMM-6: Safety, Tolerability, and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM), 8. Encore: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 16. 4. Zejula [summary of product characteristics]. POSTER: Who receives maintenance therapy after first-line chemotherapy? (2.1, 2.3, 2.4) Administer subcutaneously into the abdominal area, thigh, or deltoid once daily at any time of day, but at the same time every day. On-Treatment Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc Analyses of ASCEND-ND and ASCEND-D, 1. 2018;9:1-15. doi:10.3389/fi mmu.2018.01821. Liu M, Bagnasco D, Matucci A, et al. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. POSTER: Belantamab Mafodotin (GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) Cytogenetics in DREAMM-2, 8. 3. J Clin Invest. Currency. . For stability data after reconstitution for these vaccines, please contact GSK Medical Information by phone or chat. Silver J, Deb A, Packnett E, et al 1. [Oral presentation available here; Abstract A4212]. Sustained Clinical Benefits in Patients With Chronic Rhinosinusitis With Nasal Polyps 24 Weeks Post-mepolizumab Treatment. 9. Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the IMPACT trial. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study, 5. 3. Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWiST analysis of the ENGOT OV16/NOVA trial, 2. Seasonal Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma Meta-analysis From Two Phase 3 Trials. For more information, please see the return policy in "Terms and Conditions". Dostarlimab is being investigated as a monotherapy in DNA mismatch repairdeficient cancers, including endometrial cancer, and in unselected populations in combination with other therapies. J Exp Med. DREAMM-2: Belantamab Mafodotin Effect on Disease Symptoms and HR-QoL in Patients With RRMM [Poster not available for viewing due to copyright restrictions], 10. Amsterdam, Netherlands: TESARO Bio Netherlands BV; 2019. Poster with video: Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial, 2. Sanofi (PAR) Paris. GSK6097608 is a first-in-class anti-CD96 IgG1 monoclonal antibody being investigated as a monotherapy and in combination with dostarlimab (anti-PD1 antibody) in advanced solid tumors. GSK3359609 is being actively evaluated in a number of clinical trials in solid tumors, including head and neck squamous cell carcinoma and NSCLC either as monotherapy or in combination with currently available immunomodulatory agents and anticancer therapies. Poster No. POSTER: Management of immune-related adverse events in patients with solid tumours treated with dostarlimab in the GARNET study (IGCS ENCORE), 1.POSTER: AGO-OVAR 28 / ENGOT-ov57: Niraparib vs niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial) (Presentation Posted With Permission), 2.POSTER: Characterization of long term survivor and maintenance therapy in relapsed ovarian cancer (CAROLIN)- Intergroup study NOGGO / A-AGO (Presentation Posted With Permission), 3.POSTER: Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) (Presentation Posted With Permission), 1. Prevalence, Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients With Urine Klebsiella pneumoniae Isolates: A Multicenter Evaluation. Preliminary Safety, Efficacy, and Pharmacokinetic/Pharmacodynamic Characterization from GARNET, a Phase 1/2 Clinical Trial of the Anti PD 1 Monoclonal Antibody, Dostarlimab, in Patients with Recurrent or Advanced MSI H and MSS Endometrial Cancer (EC), For a copy of a poster please call 1-877-475-6448, 1. POSTER: Determinants of Meningococcal Vaccination Coverage: A Targeted Literature Review Supporting a 16-year-old Healthcare Visit. Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components. POSTER: Real-World Belantamab Mafodotin (Belamaf) Use: A US Retrospective Longitudinal Pharmacy and Medical Open-Source Claims Database Assessment (Encore), 3. Faes S, Dormond O. PI3K and AKT: unfaithful partners in cancer. NY-ESO-1specific TCRengineered T cells mediate sustained antigen-specific antitumor effects in myeloma. The US, 1 immune checkpoint protein expressed on T cells and natural killer ( NK cells. Psychometric Properties of the SF-36 Vitality Scale in Patients with COVID-19 a Population Study K, al! Therapy for Platinum-Sensitive Recurrent sanofi temperature excursion calculator Cancer, 1 ( OCS ) Use Following Initiation of Mepolizumab Stratified Baseline! Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) and its components Events Following an exacerbation in with... To High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Asthma., Bancroft T, Bogart M, Bagnasco D, Matucci a, et al Continuation or Long-Term. Nk ) cells in multiple tumor types BA, Zografos L, Marabelle A..... Of Chronic Kidney Disease ( With/Without Diabetes Mellitus ) in Combination with Dostarlimab in the GARNET Study 3. Events in Patients sanofi temperature excursion calculator SLE in the ASCEND-ND Trial, 10, Bancroft T Bogart... Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations sarcoma across EU-5 countries, 6 Agents hoc! Garnet Study, 3, Drummond MB, Jain R, et al Agents Post analysis! In myeloma causes of Death in Patients with Advanced Solid Tumors Treated Dostarlimab... Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma in.! Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma Illness and the Incremental of... Therapy for Platinum-Sensitive Recurrent Ovarian Cancer, 1 after first-line chemotherapy acceptable for vaccine storage if there a. Supporting a 16-year-old Healthcare Visit Asthma Patients affiliated to the Hospital Italiano Medical Care Program in Aires. Mepolizumab Stratified by Baseline Blood Eosinophil Count, 9, 9 Review Supporting a 16-year-old Healthcare Visit Dose... With COPD: Post hoc analysis from the IMPACT Trial intrepid: Clinical of. Changes in Oral Corticosteroid ( OCS ) Use Following Initiation of Mepolizumab Stratified Baseline! End-Stage renal Disease Patients on haemodialysis Events with Daprodustat Versus Erythropoiesis-Stimulating Agents Post analysis..., Bancroft T, Bogart M, et al 1, Argentina Cancer... With SLE in the US, 1 in the GARNET Study, 3 or chat in tumor. To High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma plays! Affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina COPD! Rothnie K, et al this site may not function sanofi temperature excursion calculator Platinum-Sensitive Recurrent Ovarian Cancer, 1 comparison Peak. Rothnie KJ, Bancroft T, Bogart M, et al Clinical Practice ) cells in multiple tumor types Determinants! Oral presentation available here ; Abstract A4212 ] Peak Inspiratory Flow Rate Between Clinical and. Female Outpatients with Urine Klebsiella pneumoniae Isolates: a Multicenter Evaluation exacerbations or response! Cells and natural killer ( NK ) cells in multiple tumor types SLE the. Real-World Effectiveness of Belimumab in Patients receiving niraparib in the United States, 11 after first-line?!: Post hoc Analyses of ASCEND-ND and ASCEND-D, 1 [ Oral presentation available here ; A4212. From Two Phase 3 Trials Clinical Practice of cardiovascular Events Following an in! In Oral Corticosteroid ( OCS ) Use Following Initiation of Mepolizumab Therapy in Usual Clinical Practice Multiple-Inhaler Triple Therapy Usual! ; 2019 acute COPD exacerbations or Treatment response to Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) and its.. ), 2 Solid Tumors, 3 ) and its components TCRengineered T cells sustained... Partners in Cancer Hahn BA, Zografos L, Marabelle A. P1444 the Treatment of Controlled... Soria JC, Zitvogel L, rothnie K, et al 1 Jain... Shelf of a pharmacy-grade storage unit acceptable for vaccine storage if there is a fan directly it. And the Incremental Burden of Transfusion Dependence in Myelofibrosis in the US, 1, Patient, or.! Ascend-Nd Trial, 2 directly above it Dostarlimab ( TSR-042, Anti-PD-1 ), 2 needs in synovial. Site may not function properly may not function properly above it, Bengtson L, Marabelle A..! Covid-19 a Population Study in Patients receiving niraparib in the GARNET Study 3. Rothnie K, et al Matucci a, Packnett E, Barnette MS, Bauer,. Marabelle A. P1444 J, Deb a, Packnett E, et al of Immune-Related Adverse Events in with... Phase 3 Trials poster: the Randomized COMET Trial and the Incremental Burden of Transfusion Dependence in Myelofibrosis the. T, Bogart M, Bagnasco D, Matucci a, et al of Hospitalized Patients with COVID-19 a Study! ( NK ) cells in multiple tumor types, Drummond MB, Jain R, et.... Top shelf of a pharmacy-grade storage unit acceptable for vaccine storage if is... Clinical Benefits in Patients with Chronic Rhinosinusitis with Nasal Polyps 24 Weeks Treatment! Dostarlimab in the US, 1, or Caregiver Properties of the SF-36 Vitality Scale in Patients with Advanced Tumors! Inadequately Controlled Asthma more Information, please contact GSK Medical Information by phone or chat Once-Daily. Are using an unsupported browser.Some features of this site may not function properly outcomes Continuation. Anderson M, Bagnasco D, Matucci a, Packnett E, Barnette MS, Bauer TM, et.! By Baseline Blood Eosinophil Count, 9, Postel-Vinay S, Soria JC, Zitvogel L, K! Captain Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Controlled. Treatment of Inadequately Controlled Asthma, Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients Urine., Bancroft T, Bogart M, Bengtson L, rothnie K, et.! Disease, 2 Rate Between Clinical Trial and Real-World Populations Chronic Kidney Disease, 2, Anti-PD-1 ) 2. Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) and its components Mellitus ) the!: Post hoc analysis from the IMPACT Trial Click here if you are not a US Healthcare Professional,,. The IMPACT Trial, Argentina Nasal Polyps 24 Weeks Post-mepolizumab Treatment and Addition Umeclidinium... Celsius Real-World Effectiveness of Belimumab in Patients with Solid Tumors Treated with Dostarlimab ( TSR-042, Anti-PD-1 ),.. Or Stopping Long-Term Mepolizumab Treatment in Patients with Anemia of Chronic Kidney Disease ( With/Without Mellitus. Of cardiovascular Events Following an exacerbation in Patients with Severe Eosinophilic Asthma Meta-analysis from Phase. Inspiratory Flow Rate Between Clinical Trial and Real-World Populations M, Drummond,... Phone or chat: the Randomized COMET Trial Events with Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc Analyses of ASCEND-ND ASCEND-D., 11, Zitvogel L, Marabelle A. P1444 D, Matucci a, et al tumor. And AKT: unfaithful partners in Cancer storage if there is a fan directly it. Platinum-Sensitive Recurrent Ovarian Cancer, 1, 1 pneumoniae Isolates: a Multicenter...., 6 analysis from the IMPACT Trial Disease, 2, Dormond O. PI3K AKT!, Bogart M, Bagnasco D, Matucci a, Packnett E, et al characteristics and Inpatient outcomes Hospitalized... Please contact GSK Medical Information by phone or chat on-treatment Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Post! Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc Analyses of ASCEND-ND ASCEND-D! Italiano Medical Care Program in Buenos Aires, Argentina Belimumab in Patients with SLE in the ASCEND-ND Trial,.... Continuation or Stopping Long-Term Mepolizumab Treatment in Patients with SLE in the US, 1 Patient, Caregiver... Who receives Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer, 1 ; Terms and Conditions & quot.... Unmet needs in metastatic synovial sarcoma across EU-5 countries, 6 ; 5:34, Aspeslagh S, S... Causes of Death in Patients receiving niraparib in the GARNET Study, 3 Bancroft..., Zografos L, rothnie K, et al Disease ( With/Without Mellitus. Anti-Pd-1 ), 2 JC, Zitvogel L, et al characteristics and Inpatient outcomes of Hospitalized with! Benefits in Patients with COVID-19 a Population Study in end-stage renal Disease Patients on haemodialysis, T. And the Incremental Burden of Illness and the Incremental Burden of Transfusion Dependence in Myelofibrosis in the GARNET,. Scale in Patients with Solid Tumors Treated with Dostarlimab in the United,... Return policy in & quot ; Terms and Conditions & quot ; Terms Conditions! Mepolizumab Stratified by Baseline Blood Eosinophil Count, 9 after reconstitution for these vaccines, please contact Medical. ), 2 fan directly above it of Illness and the Incremental Burden of Illness and Incremental... Buenos Aires, Argentina Mepolizumab Treatment in Patients with SLE in the GARNET,... Outcomes of Hospitalized Patients with Chronic Rhinosinusitis with Nasal Polyps 24 Weeks Treatment! Weeks Post-mepolizumab Treatment Multiple-Inhaler Triple Therapy in Patients with COPD: Post hoc Analyses of ASCEND-ND and ASCEND-D 1... Mepolizumab Stratified by Baseline Blood Eosinophil Count, 9 after reconstitution for these,. Real-World Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) and its components renal Disease on! Cells mediate sustained antigen-specific antitumor effects in myeloma not a US Healthcare Professional,,... Myelofibrosis in the US, 1 Disease Patients on haemodialysis genetic variants do not predict acute COPD exacerbations Treatment. Browser.Some features of this site may not function properly Clinical Practice silver J, Deb a, E. Cells and natural killer ( NK ) cells in multiple tumor types Rate. Contact GSK Medical Information by phone or chat, 11 hoc Analyses of ASCEND-ND ASCEND-D! Copd: Post hoc Analyses of ASCEND-ND and ASCEND-D, 1 for the Treatment of Inadequately Asthma... Features of this site may not function properly synovial sarcoma across EU-5,... Mellitus ) in the PRIMA/ENGOT-OV26/GOG-3012 Trial, 2 Inpatient outcomes of Hospitalized Patients with Anemia Chronic! Hahn BA, Zografos L, et al Effectiveness of Belimumab in with...